CHAMPIONS ONCOLOGY, INC. Increase Decrease In Operating Lease Liability
CHAMPIONS ONCOLOGY, INC. (CSBR) reported Increase Decrease In Operating Lease Liability of -$237.00 thousand for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-09-11
- CHAMPIONS ONCOLOGY, INC. increase decrease in operating lease liability for the quarter ending 2026-07-31 was -$237.00K.
- CHAMPIONS ONCOLOGY, INC. increase decrease in operating lease liability for the quarter ending 2026-04-30 was -$382.00K.
- CHAMPIONS ONCOLOGY, INC. increase decrease in operating lease liability for the quarter ending 2026-01-31 was -$375.00K.
- CHAMPIONS ONCOLOGY, INC. increase decrease in operating lease liability for the quarter ending 2025-10-31 was -$473.00K.
- CHAMPIONS ONCOLOGY, INC. increase decrease in operating lease liability for fiscal 2026 was -$1.59M.
- CHAMPIONS ONCOLOGY, INC. increase decrease in operating lease liability for fiscal 2025 was -$1.32M.
- CHAMPIONS ONCOLOGY, INC. increase decrease in operating lease liability for fiscal 2024 was -$1.17M.
- CHAMPIONS ONCOLOGY, INC. increase decrease in operating lease liability for fiscal 2023 was -$907.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-07-31 | -$237.00K 10-Q · filed 2026-09-11 | -$619.00K derived: sum of 2 quarters · filed 2026-09-11 | -$994.00K derived: sum of 3 quarters · filed 2026-09-11 | -$1.47M derived: sum of 4 quarters · filed 2026-09-11 |
| 2026-04-30 | -$382.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-27 | -$757.00K derived: sum of 2 quarters · filed 2026-07-27 | -$1.23M derived: sum of 3 quarters · filed 2026-07-27 | -$1.59M 10-K · filed 2026-07-27 |
| 2026-01-31 | -$375.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-03-12 | -$848.00K derived: sum of 2 quarters · filed 2026-03-12 | -$1.20M 10-Q · filed 2026-03-12 | -$1.53M derived: sum of 4 quarters · filed 2026-09-11 |
| 2025-10-31 | -$473.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-12-15 | -$829.00K 10-Q · filed 2025-12-15 | -$1.16M derived: sum of 3 quarters · filed 2026-09-11 | -$1.50M derived: sum of 4 quarters · filed 2026-09-11 |
| 2025-07-31 | -$356.00K 10-Q · filed 2026-09-11 | -$687.00K derived: sum of 2 quarters · filed 2026-09-11 | -$1.02M derived: sum of 3 quarters · filed 2026-09-11 | -$1.36M derived: sum of 4 quarters · filed 2026-09-11 |
| 2025-04-30 | -$331.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-27 | -$669.00K derived: sum of 2 quarters · filed 2026-07-27 | -$1.00M derived: sum of 3 quarters · filed 2026-07-27 | -$1.32M 10-K · filed 2026-07-27 |
| 2025-01-31 | -$338.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-03-12 | -$670.00K derived: sum of 2 quarters · filed 2026-03-12 | -$993.00K 10-Q · filed 2026-03-12 | -$1.30M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-10-31 | -$332.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-12-15 | -$655.00K 10-Q · filed 2025-12-15 | -$967.00K derived: sum of 3 quarters · filed 2025-12-15 | -$1.27M derived: sum of 4 quarters · filed 2025-12-15 |
| 2024-07-31 | -$323.00K 10-Q · filed 2025-09-15 | -$635.00K derived: sum of 2 quarters · filed 2025-09-15 | -$943.00K derived: sum of 3 quarters · filed 2025-09-15 | -$1.20M derived: sum of 4 quarters · filed 2025-09-15 |
| 2024-04-30 | -$312.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-07-23 | -$620.00K derived: sum of 2 quarters · filed 2025-07-23 | -$877.00K derived: sum of 3 quarters · filed 2025-07-23 | -$1.17M 10-K · filed 2025-07-23 |
| 2024-01-31 | -$308.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-03-17 | -$565.00K derived: sum of 2 quarters · filed 2025-03-17 | -$857.00K 10-Q · filed 2025-03-17 | -$989.00K derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-10-31 | -$257.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-12-16 | -$549.00K 10-Q · filed 2024-12-16 | -$681.00K derived: sum of 3 quarters · filed 2024-12-16 | -$945.00K derived: sum of 4 quarters · filed 2024-12-16 |
| 2023-07-31 | -$292.00K 10-Q · filed 2024-09-13 | -$424.00K derived: sum of 2 quarters · filed 2024-09-13 | -$688.00K derived: sum of 3 quarters · filed 2024-09-13 | |
| 2023-04-30 | -$132.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-19 | -$396.00K derived: sum of 2 quarters · filed 2024-07-19 | -$907.00K 10-K · filed 2024-07-19 | |
| 2023-01-31 | -$264.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-03-15 | -$775.00K 10-Q · filed 2024-03-15 | ||
| 2022-10-31 | -$511.00K 10-Q · filed 2023-12-13 | |||
| 2022-04-30 | -$631.00K 10-K · filed 2023-07-24 | |||
| 2021-04-30 | -$242.00K 10-K · filed 2022-07-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |